Details

Autor(en) / Beteiligte

• Verma, Vivek
• Simone, Charles B.
• Allen, Pamela K.
• Gajjar, Sameer R.
• Shah, Chirag
• Zhen, Weining
• Harkenrider, Matthew M.
• Hallemeier, Christopher L.
• Jabbour, Salma K.
• Matthiesen, Chance L.
• Braunstein, Steve E.
• Lee, Percy
• Dilling, Thomas J.
• Allen, Bryan G.
• Nichols, Elizabeth M.
• Attia, Albert
• Zeng, Jing
• Biswas, Tithi
• Paximadis, Peter
• Wang, Fen
• Walker, Joshua M.
• Stahl, John M.
• Daly, Megan E.
• Decker, Roy H.
• Hales, Russell K.
• Willers, Henning
• Videtic, Gregory M.M.
• Mehta, Minesh P.
• Lin, Steven H.

Titel

Multi-Institutional Experience of Stereotactic Ablative Radiation Therapy for Stage I Small Cell Lung Cancer

Ist Teil von

• International journal of radiation oncology, biology, physics, 2017-02, Vol.97 (2), p.362-371

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2017

Quelle

MEDLINE

Beschreibungen/Notizen

• For inoperable stage I (T1-T2N0) small cell lung cancer (SCLC), national guidelines recommend chemotherapy with or without conventionally fractionated radiation therapy. The present multi-institutional cohort study investigated the role of stereotactic ablative radiation therapy (SABR) for this population. The clinical and treatment characteristics, toxicities, outcomes, and patterns of failure were assessed in patients with histologically confirmed stage T1-T2N0M0 SCLC. Kaplan-Meier analysis was used to evaluate the survival outcomes. Univariate and multivariate analyses identified predictors of outcomes. From 24 institutions, 76 lesions were treated in 74 patients (median follow-up 18 months). The median age and tumor size was 72 years and 2.5 cm, respectively. Chemotherapy and prophylactic cranial irradiation were delivered in 56% and 23% of cases, respectively. The median SABR dose and fractionation was 50 Gy and 5 fractions. The 1- and 3-year local control rate was 97.4% and 96.1%, respectively. The median disease-free survival (DFS) duration was 49.7 months. The DFS rate was 58.3% and 53.2% at 1 and 3 years, respectively. The median, 1-year, and 3-year disease-specific survival was 52.3 months, 84.5%, and 64.4%, respectively. The median, 1-year, and 3-year overall survival (OS) was 17.8 months, 69.9%, and 34.0% respectively. Patients receiving chemotherapy experienced an increased median DFS (61.3 vs 9.0 months; P=.02) and OS (31.4 vs 14.3 months; P=.02). The receipt of chemotherapy independently predicted better outcomes for DFS/OS on multivariate analysis (P=.01). Toxicities were uncommon; 5.2% experienced grade ≥2 pneumonitis. Post-treatment failure was most commonly distant (45.8% of recurrence), followed by nodal (25.0%) and “elsewhere lung” (20.8%). The median time to each was 5 to 7 months. From the findings of the largest report of SABR for stage T1-T2N0 SCLC to date, SABR (≥50 Gy) with chemotherapy should be considered a standard option.